Red Day Pharmaceutical Products Blood Must Net Injection included in the New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial 8th Edition)

Guide reading: blood must be net injection as one of the company's main products, the exclusive production of Chinese medicine class II new drugs, the national health insurance catalog (class B) varieties.
19, 2020, the National Health and Health Commission and the State Administration of Traditional Chinese Medicine jointly released the New Coronavirus Pneumonia Treatment Program (Trial 8th Edition).
Tianjin Red Day Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") products blood must be net injection, respectively, included in the treatment of heavy, dangerous heavy cases of other treatment measures, as well as Chinese medicine treatment of the clinical treatment period (confirmed cases) heavy (gas camp two certificate), critical heavy (internal and external evidence) recommended medication.
blood must be net injection as one of the company's main products, is the company has independent intellectual property rights, the exclusive production of Chinese medicine class II new drugs, the national health insurance catalog (Class B) varieties.
Blood Must Net Injection is currently the only SFDA approved treatment of systemic inflammatory response syndrome (SIRS), sepsis (Sepsis), multi-organ dysfunction syndrome (MODS) of the country's second class of new drugs, with patent protection.
June 2019, the results of the study on the treatment of severe pneumonia by blood-purification injections were published in the international journal Critical Care Medicine (CCM), marking the results of which have been rigorously reviewed and unanimously endorsed by international peer experts.
the first quarter of 2020, the net injection of blood must achieve operating income of 178 million yuan, accounting for 15.78 percent of the company's operating income.
Blood must be net injection as a representative drug for the treatment of severe pneumonia, sepsis and multi-organ dysfunction syndrome, because of the outstanding clinical efficacy, evidence-based evidence solid foundation, by the vast number of Chinese and Western medical clinical experts recognized and recommended.
, as a Chinese medicine and Western medicine treatment program jointly recommended traditional Chinese medicine, has been continuously included in the new coronavirus pneumonia diagnosis and treatment program (trial fourth edition), (trial fifth edition), (trial sixth edition), (trial seventh edition), (trial eighth edition).
During the outbreak of new coronary pneumonia, the mechanism and clinical research on the efficacy of blood-must-net injections to treat new coronary pneumonia showed good results, and the research results were awarded the "First Prize of Scientific and Technological Progress" in Tianjin city by expert evaluation and acceptance organized by The Tianjin Science and Technology Bureau.
and the review by the National Drug Administration, an adaptation "can be used for severe, critical systemic inflammatory response syndrome or/and multiple organ failure of the new coronavirus pneumonia" was added to the product specification.
because of the clear therapeutic value reflected in the clinical treatment practice of heavy and critical cases of new coronary pneumonia, blood must be net injection is included in the "three-drug three-way" of effective anti-epidemic drugs in Chinese medicine.
.